SLC5A2 and type 2 diabetes mellitus: The efficacy of the sodium-glucose co-transporter-2 (SGLT-2) inhibitor DAPA in enhancing cardiovascular outcomes among individuals diagnosed with type 2 diabetes has been substantiated through clinical research44.